Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Baseline Characteristics
100%
Pseudomonas Aeruginosa (P. aeruginosa)
100%
Protocol Features
100%
Brensocatib
100%
Non-cystic Fibrosis Bronchiectasis
100%
Aspen
100%
Bronchiectasis
80%
Lung Function
40%
Index Score
40%
Moderate to Severe
20%
Quality of Life
20%
Clinical Data
20%
Cough
20%
Antibiotic Use
20%
Placebo
20%
Etiology
20%
Design Characteristics
20%
Disease Severity
20%
Adult Patients
20%
Regional Variation
20%
Latin America (LATAM)
20%
Treatment Patterns
20%
Inhaled Corticosteroid Therapy
20%
Macrolides
20%
Clinical Trial Design
20%
Clinical History
20%
Sputum Production
20%
Exacerbation Rate
20%
Long-term Antibiotics
20%
Recurrent Respiratory Infections
20%
Dipeptidyl Peptidase 1
20%
Treatment Profiles
20%
Characteristic Profile
20%
Treatment Period
20%
Infection Detection
20%
Reversible Inhibitors
20%
Medicine and Dentistry
Cystic Fibrosis
100%
Bronchiectasis
100%
Pseudomonas aeruginosa
71%
Lung
28%
Placebo
14%
Quality of Life
14%
Disease Severity
14%
Respiratory Tract Infection
14%
Sputum
14%
Macrolide
14%
Clinical Trial Design
14%
Chronic Cough
14%
Antimicrobial Agent
14%
Etiology
14%
Corticosteroid
14%
Dipeptidyl Peptidase
14%
Oral
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Bronchiectasis
100%
Pseudomonas aeruginosa
71%
Placebo
14%
Disease Severity
14%
Respiratory Tract Infection
14%
Macrolide
14%
Clinical Trial Design
14%
Antimicrobial Agent
14%
Etiology
14%
Chronic Cough
14%
Corticosteroid
14%
Dipeptidyl Peptidase
14%
Nursing and Health Professions
Cystic Fibrosis
100%
Bronchiectasis
100%
Placebo
14%
Disease Severity
14%
Corticosteroid
14%
Chronic Cough
14%
Respiratory Tract Infection
14%
Macrolide
14%
Etiology
14%
Antimicrobial Agent
14%
Quality of Life
14%
Clinical Trial
14%
Immunology and Microbiology
Pseudomonas aeruginosa
100%
Lung
40%
Infectious Disease
20%
Sputum
20%
Antimicrobial Agent
20%
Infection
20%